"Lomustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent of value against both hematologic malignancies and solid tumors.
| Descriptor ID |
D008130
|
| MeSH Number(s) |
D02.654.692.440 D02.948.594.440
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lomustine".
Below are MeSH descriptors whose meaning is more specific than "Lomustine".
This graph shows the total number of publications written about "Lomustine" by people in this website by year, and whether "Lomustine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lomustine" by people in Profiles.
-
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
-
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93.
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8.
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34.
-
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9.
-
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 1999 Sep 22; 53(5):1141-3.
-
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
-
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol. 1986 Oct; 4(10):1443-54.